TICKERNOMICS Sign up
Last Update: 2024-12-27 15:25:26
Altimmune Inc. ( ALT ) https://altimmune.com
8.00USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-31.15%
ALT
SPY
32.66%
-8.57%
ALT
SPY
108.59%
ALT
344.44%
SPY
302.52%
-98.42%
ALT
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
568.68
431.07
2.19
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-5.49
10936.12
4.26
-13.43
0.00
-4.19
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-495340.00
100.00
-514155.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
6.9328
-87.05
-53.08
0.71
Other Earnings and Cash Flow Stats:
Altimmune Inc. ( ALT ) Net Income TTM ($MM) is -103.52
Altimmune Inc. ( ALT ) Operating Income TTM ($MM) is -99.51
Altimmune Inc. ( ALT ) Owners' Earnings Annual ($MM) is 0.00
Altimmune Inc. ( ALT ) Current Price to Owners' Earnings ratio is 0.00
Altimmune Inc. ( ALT ) EBITDA TTM ($MM) is -97.41
Altimmune Inc. ( ALT ) EBITDA Margin is -514155.00%
Capital Allocation:
Altimmune Inc. ( ALT ) has paid 0.00 dividends per share and bought back -17.451433 million shares in the past 12 months
Altimmune Inc. ( ALT ) has reduced its debt by 3.805 million USD in the last 12 months
Capital Structure:
Altimmune Inc. ( ALT ) Interest-bearing Debt ($MM) as of last quarter is 1
Altimmune Inc. ( ALT ) Annual Working Capital Investments ($MM) are 5
Altimmune Inc. ( ALT ) Book Value ($MM) as of last quarter is 133
Altimmune Inc. ( ALT ) Debt/Capital as of last quarter is 1%
Other Balance Sheet Stats:
Altimmune Inc. ( ALT ) has 31 million in cash on hand as of last quarter
Altimmune Inc. ( ALT ) has 8 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Altimmune Inc. ( ALT ) has 71 common shares outstanding as of last quarter
Altimmune Inc. ( ALT ) has 0 million USD of preferred stock value
Academic Scores:
Altimmune Inc. ( ALT ) Altman Z-Score is 17.27 as of last quarter
Altimmune Inc. ( ALT ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
Altimmune Inc. ( ALT ) largest shareholder is owning shares at 0.00 ($MM) value
Drutz David(an insider) Sold 8184 shares of Altimmune Inc. ( ALT ) for the amount of $56305.92 on 2024-08-19
0.79% of Altimmune Inc. ( ALT ) is held by insiders, and 56.57% is held by institutions
Altimmune Inc. ( ALT ) went public on 2005-10-06
Other Altimmune Inc. ( ALT ) financial metrics:
FCF:-78.13
Unlevered Free Cash Flow:0.00
EPS:-1.29
Operating Margin:-495340.00
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-68.51
Beta:0.71
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Altimmune Inc. ( ALT ) :
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.